CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Marksans Pharma Ltd (Parent) is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Marksans Pharma Ltd (Parent)
21 Lotus Business Park
, Off New Link Road,, Andheri (W)
Phone: +91 2240012000p:+91 2240012000 MUMBAI, 400053  India Fax: +91 2240012099f:+91 2240012099
Business Summary
Marksans Pharma Limited is an India-based pharmaceutical company. The Company is primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulations. The Company produces goods across various therapeutic areas, such as pain management, cough and cold, cardiovascular and central nervous system, anti-diabetic, gastrointestinal, hormonal treatment, and anti-allergic, among others. The Company operates four manufacturing facilities across India, the United Kingdom and the United States. The Company manufactures oral solid tablets, soft gelatin capsules and hard capsules in Goa. It also manufactures non-sterile liquids, ointments and powder products and caters to the United Kingdom, West Africa and the Middle East, which is located in the United Kingdom. The Company has spread its facility to over 7000 square meters and manufactures tablets and capsules in the United States.
(Source: ARS)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/20233/31/2022Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
5122 Drugs, drug proprietaries, and druggists' sundries
8731 Commercial physical and biological research
6719 Offices of holding companies, not elsewhere classified

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board, Managing Director Mark B.Saldanha 49 10/6/2015 10/6/2015
Chief Financial Officer JitendraSharma 52
Compliance Officer, Company Secretary and Legal Manager HarshavardhanPanigrahi 1/1/2022 2/16/2009
7 additional Officers and Directors records available in full report.

Business Names
Business Name
Marksans Pharma Limited
Marksans Pharma Limited (Parent)

General Information
Number of Employees: 718 (As of 3/31/2012)
Outstanding Shares: 453,163,746 (As of 3/31/2023)
Shareholders: 45,503
Fax Number: +91 2240012099


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, September 27, 2023